Recent Highlights
All Stories for Roche
Coronavirus World Update, May 15: Global death toll crosses 300,000, Italy to allow movement, Japan eases restrictions
Myupchar • 5 years agoOver 4.5 million people have been confirmed to be COVID-19 positive in the world so far. Of these, 1.7 million have recovered and over 300,000 have died.
Coronavirus Global Roundup, May 4: No new cases in New Zealand, 5% rise in deaths in Canada, 27,000 new cases in the US
Myupchar • 5 years agoMore than 3.5 million people have been affected by COVID-19 and more than 247,000 people have succumbed to the disease.
TCS Collaborates With Roche
Fp Archives • 18 years agoTCS has entered into a collaboration with Swiss healthcare company Roche to provide services related to drug development processes.
Another setback: India rejects patent on Pfizer's arthritis drug
Fp Archives • 10 years agoPfizer is reviewing its options for further action, a Mumbai-based company spokesman said in an emailed statement.
Biocon to start selling breast cancer drug next month
Fp Archives • 11 years agoCANMAb will be available at about 25 percent discount to the current list price of the reference product - Roche's Herceptin - in India, which is already significantly lower than its price in developed markets, it added.<br /><br />
India revokes Roche patent; questions high price of drug
Fp Archives • 12 years agoThe Intellectual Property Appellate Board (IPAB) cited a lack of evidence that the drug was any better than existing treatments and its high price as reasons for the decision.
All-cash deal: Roche to buy US biotech firm InterMune for $8.3 bn
Fp Archives • 11 years agoRoche Holding AG has agreed to buy US biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.<br />
Not just India: UK regulator says Roche’s new breast cancer drug too costly
Fp Staff • 12 years agoThe National Institute for Care and Excellence (NICE) of the UK has rejected Roche’s latest breast cancer drug Perjeta because it is too expensive.